Limited Coverage Drugs - buprenorphine

Generic Name

buprenorphine

Strength

100 mg/0.5 mL, 300 mg/1.5 mL

Form

extended-release subcutaneous injection
 
Special Authority Criteria Approval Period

For the management of moderate to severe opioid use disorder in adult patients:

Patients must be induced and clinically stabilized on an equivalent of 8 mg to 24 mg of transmucosal buprenorphine-naloxone for a minimum of seven days.

1 year

Practitioner Exemptions

No practitioner exemptions.

Special Notes

  • Patients are under the care of a health care provider with experience in the diagnosis and management of opioid use disorder.
  • As stated in the Health Canada indication, buprenorphine extended-release injection should be used as part of a complete treatment plan that includes counselling and psychosocial support.
  •  As stated in the Health Canada indication, buprenorphine extended-release injection must be administered subcutaneously in the abdominal region by a healthcare provider.

Special Authority Request Form(s)

5328 - General Special Authority Request Form